| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.17 | 0.0004 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.16 | 0.0004 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | -0.16 | 0.0007 |
| mRNA | paclitaxel | CCLE | pan-cancer | AAC | -0.16 | 0.0008 |
| mRNA | 17-AAG | CCLE | pan-cancer | AAC | -0.15 | 0.002 |
| mRNA | Topotecan | CCLE | pan-cancer | AAC | -0.11 | 0.01 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | -0.12 | 0.02 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | -0.11 | 0.03 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | -0.11 | 0.04 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | -0.097 | 0.05 |